HealthExperimental mRNA cancer vaccine plus Keytruda cuts melanoma recurrence or death risk by 42%
An experimental mRNA cancer vaccine combined with the approved drug Keytruda reduced patients’ risk of cancer returning after surgery or death by 42% compared with Keytruda alone, pointing to a new approach to treating melanoma.
C
CNN★★★☆☆2026-10-22 23:02Original
Experimental mRNA cancer vaccine plus Keytruda cuts melanoma recurrence or death risk by 42%